These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 14639052)

  • 1. Dose-adjusted cyclosporine c2 in a patient with jejunoileal bypass as compared to seven other liver transplant recipients.
    Chenhsu RY; Wu Y; Katz D; Rayhill S
    Ther Drug Monit; 2003 Dec; 25(6):665-70. PubMed ID: 14639052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new oral formulation of cyclosporine for early oral immunosuppressive therapy in liver transplant recipients.
    Winkler M; Haller G; Oldhafer K; Bechstein WO; Kattner A; Maibücher A; Färber L; Ringe B; Christians U; Neuhaus P; Pichlmayr R
    Transplantation; 1996 Oct; 62(8):1063-8. PubMed ID: 8900302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg.
    Ganschow R; Richter A; Grabhorn E; Schulz A; von Hugo A; Mir TS; Broering DC; Rogiers X; Hinrichs B; Burdelski M
    Pediatr Transplant; 2004 Apr; 8(2):185-8. PubMed ID: 15049800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients.
    Bonhomme-Faivre L; Devocelle A; Saliba F; Chatled S; Maccario J; Farinotti R; Picard V
    Transplantation; 2004 Jul; 78(1):21-5. PubMed ID: 15257034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
    Canadian Neoral Renal Transplantation Study Group
    Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
    Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
    Schädeli F; Marti HP; Frey FJ; Uehlinger DE
    Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients.
    Dunn S; Cooney G; Sommerauer J; Lindsay C; McDiarmid S; Wong RL; Chang CT; Smith HT; Choc MG
    Transplantation; 1997 Jun; 63(12):1762-7. PubMed ID: 9210501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine monitoring in the early post-transplant period in pediatric liver transplant recipients.
    Frauca E; Diaz MC; de la Vega A; Hierro L; Camarena C; Muñoz Bartolo G; Díez R; Murcia J; Gámez M; Sanchez Peinado C; López Santamaría M; Andrés I; Jara P
    Pediatr Transplant; 2007 Aug; 11(5):530-5. PubMed ID: 17631022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a three-year prospective study of C2 monitoring in long-term renal transplant recipients receiving cyclosporine microemulsion.
    Citterio F; Scatà MC; Romagnoli J; Nanni G; Castagneto M
    Transplantation; 2005 Apr; 79(7):802-6. PubMed ID: 15818322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circadian variations in cyclosporine C2 concentrations during the first 2 weeks after liver transplantation.
    Baraldo M; Risaliti A; Bresadola F; Chiarandini P; Dalla Rocca G; Furlanut M
    Transplant Proc; 2003 Jun; 35(4):1449-51. PubMed ID: 12826188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
    Midtvedt K; Fauchald P; Bergan S; Høieggen A; Hallan S; Svarstad E; Bergrem H; Eriksen BO; Pfeffer PF; Dalen I; Leivestad T
    Transplantation; 2003 Oct; 76(8):1236-8. PubMed ID: 14578761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of cyclosporine microemulsion and tacrolimus in 39 recipients of living donor liver transplantation.
    Tanaka K; Lake J; Villamil F; Levy G; Marotta P; Mies S; de Hemptinne B; Moench C
    Liver Transpl; 2005 Nov; 11(11):1395-402. PubMed ID: 16237691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
    Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation.
    Levy G; Villamil F; Samuel D; Sanjuan F; Grazi GL; Wu Y; Marotta P; Boillot O; Muehlbacher F; Klintmalm G;
    Transplantation; 2004 Jun; 77(11):1632-8. PubMed ID: 15201658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
    J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
    Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals.
    Atiq F; Hameli E; Broers AEC; Doorduijn JK; Van Gelder T; Andrews LM; Koch BCP; Versmissen J; de Winter BCM
    Eur J Clin Pharmacol; 2018 Jun; 74(6):767-773. PubMed ID: 29500599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.